Stockreport

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

Summit Therapeutics Inc.  (SMMT) 
Last summit therapeutics inc. earnings: 6/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: summitplc.com/investors/investor-centre
PDF FDA Grants Fast Track Designation for Ivonescimab in 2L+ EGFRm NSCLCHARMONi Completed Enrollment for Summit’s First Sponsored Study Evaluating IvonescimabTopline data fr [Read more]